TopoTarget's Totect achieves 2007 gains

Danish biotechnology firm TopoTarget AS says that its product Totect (dexrazone; known as Savene in Europe) has achieved positive sales growth on both sides of the Atlantic. The agent is the "gold standard" therapy for anthracycline extravasation that can occur during chemotherapy.

Revenue from Savene in Europe reached 19.3 million Danish kroner ($3.9 million) in 2007, up from 2.0 million kroner the previous year. In the USA, where Totect was launched in the third quarter of last year (Marketletter October 22, 2007), sales amounted to 2.6 million kroner.

TopoTarget also reported that, as part of its European distribution strategy, it has signed an agreement with Italy's Adienne Pharma covering provision of the drug in the country. Financial terms were not provided.